Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526980 | 0.93 | HPGD (0.56) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL6796608 | 0.87 | OPRD1 (0.60) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL4576604 | 0.85 | ALDH1A1 (0.65) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL1986972 | 0.82 | OPRD1 (0.62) | OPRD1OPRM1 | |
| SCHEMBL6795500 | 0.82 | HPGD (0.52) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL6797369 | 0.82 | OPRD1 (0.60) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL72112 | 0.80 | HPGD (0.85) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL12360012 | 0.80 | OPRD1 (0.53) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL1934353 | 0.80 | OPRD1 (0.53) | ALDH1A1HPGDMAPTOPRD1OPRK1 | |
| SCHEMBL6777499 | 0.80 | ALDH1A1 (0.58) | ALDH1A1HPGDMAPTOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-8865721-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575169-B2 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8551998-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | CHANG KWEN-JEN (US) | 2013-02-28 | — | — | US | disclosed |
| EP-1469850-B1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | disclosed |
| EP-1469850-A4 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1469850-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040138228-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1408037-A1 | Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-6680321-B1 | 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS | ASTRAZENECA CANADA, INC. (CA) | 2004-01-20 | — | — | US | disclosed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | disclosed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6130222-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0915855-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997023466-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | ALDH1A1 3272/4885HPGD 1088/4885MAPT 1722/4885 |
| US-20040138228-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | ALDH1A1 539/4885HPGD 517/4885MAPT 2353/4885 |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | ALDH1A1 2489/4885HPGD 818/4885MAPT 2357/4885 |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | ALDH1A1 3272/4885HPGD 1088/4885MAPT 1722/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | ALDH1A1 3272/4885HPGD 1088/4885MAPT 1722/4885 |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | ALDH1A1 2489/4885HPGD 818/4885MAPT 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.